Electromed
Market Cap
US$92.9m
Last Updated
2020/02/17 00:55 UTC
Data Sources
Company Financials +
Executive Summary
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages in the United States and internationally.
Snowflake Analysis
Flawless balance sheet with solid track record.
Similar Companies
Share Price & News
How has Electromed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ELMD's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.5%
ELMD
2.2%
US Medical Equipment
1.5%
US Market
1 Year Return
90.6%
ELMD
22.1%
US Medical Equipment
20.1%
US Market
Return vs Industry: ELMD exceeded the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: ELMD exceeded the US Market which returned 20.1% over the past year.
Shareholder returns
| ELMD | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 2.2% | 1.5% |
| 30 Day | 16.2% | 1.0% | 1.4% |
| 90 Day | 9.9% | 8.7% | 8.7% |
| 1 Year | 90.6%90.6% | 23.0%22.1% | 22.7%20.1% |
| 3 Year | 121.4%121.4% | 84.6%79.4% | 50.1%40.5% |
| 5 Year | 378.6%378.6% | 117.1%94.4% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Electromed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Electromed, Inc. Just Beat EPS By 250%: Here's What Analysts Think Will Happen Next3 weeks ago | Simply Wall St
Did Electromed, Inc.'s (NYSEMKT:ELMD) Recent Earnings Growth Beat The Trend?1 month ago | Simply Wall St
If You Like EPS Growth Then Check Out Electromed (NYSEMKT:ELMD) Before It's Too LateValuation
Is Electromed undervalued compared to its fair value and its price relative to the market?
25.23x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ELMD ($10.96) is trading above our estimate of fair value ($10.88)
Significantly Below Fair Value: ELMD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ELMD is good value based on its PE Ratio (25.2x) compared to the Medical Equipment industry average (47.1x).
PE vs Market: ELMD is poor value based on its PE Ratio (25.2x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: ELMD is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: ELMD is good value based on its PB Ratio (3.3x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is Electromed forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
8.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELMD's forecast earnings growth (8.6% per year) is above the savings rate (1.7%).
Earnings vs Market: ELMD's earnings (8.6% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: ELMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: ELMD's revenue (12.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: ELMD's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELMD's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Electromed performed over the past 5 years?
17.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ELMD has high quality earnings.
Growing Profit Margin: ELMD's current net profit margins (11.1%) are higher than last year (6.2%).
Past Earnings Growth Analysis
Earnings Trend: ELMD's earnings have grown by 17.7% per year over the past 5 years.
Accelerating Growth: ELMD's earnings growth over the past year (94.4%) exceeds its 5-year average (17.7% per year).
Earnings vs Industry: ELMD earnings growth over the past year (94.4%) exceeded the Medical Equipment industry 7.1%.
Return on Equity
High ROE: ELMD's Return on Equity (12.8%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Electromed's financial position?
Financial Position Analysis
Short Term Liabilities: ELMD's short term assets ($26.3M) exceed its short term liabilities ($3.0M).
Long Term Liabilities: ELMD's short term assets ($26.3M) exceed its long term liabilities ($39.6K).
Debt to Equity History and Analysis
Debt Level: ELMD is debt free.
Reducing Debt: ELMD has no debt compared to 5 years ago when its debt to equity ratio was 9.4%.
Debt Coverage: ELMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ELMD has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: ELMD has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ELMD's debt is covered by short term assets.
Next Steps
Dividend
What is Electromed's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ELMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ELMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ELMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ELMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.8yrs
Average management tenure
CEO
Kathleen Skarvan (63yo)
7.2yrs
Tenure
US$867,573
Compensation
Ms. Kathleen S. Skarvan has been the Chief Executive Officer of Electromed, Inc. since December 1, 2012 and its President since August 28, 2015. Ms. Skarvan served as Vice President of Operations at OEM Fa ...
CEO Compensation Analysis
Compensation vs Market: Kathleen's total compensation ($USD867.57K) is above average for companies of similar size in the US market ($USD521.92K).
Compensation vs Earnings: Kathleen's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.2yrs | US$867.57k | 1.52% $1.4m | |
| CFO, Principal Accounting Officer & Financial Controller | 8.3yrs | US$463.32k | 0.62% $575.4k | |
| VP of Sales | 0.8yrs | no data | no data | |
| Secretary | 0yrs | no data | no data | |
| Vice President of Reimbursement | 2.3yrs | no data | no data |
4.8yrs
Average Tenure
63yo
Average Age
Experienced Management: ELMD's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 7.2yrs | US$867.57k | 1.52% $1.4m | |
| Independent Director | 5.5yrs | US$24.60k | 0.21% $199.3k | |
| Independent Director | 0.5yrs | no data | 0.035% $32.9k | |
| Independent Vice Chairman of the Board | 3.1yrs | US$32.40k | 0.25% $228.2k | |
| Independent Director | 15.1yrs | US$23.60k | 7.21% $6.7m | |
| Independent Chairman | 7.8yrs | US$45.90k | 6.66% $6.2m | |
| Member of Bronchiectasis Advisory Board | 2.5yrs | no data | no data | |
| Member of Bronchiectasis Advisory Board | 2.5yrs | no data | no data | |
| Member of Bronchiectasis Advisory Board | 2.5yrs | no data | no data |
3.1yrs
Average Tenure
65.5yo
Average Age
Experienced Board: ELMD's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Electromed, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Electromed, Inc.
- Ticker: ELMD
- Exchange: AMEX
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$92.924m
- Shares outstanding: 8.48m
- Website: https://www.smartvest.com
Number of Employees
Location
- Electromed, Inc.
- 500 Sixth Avenue NW
- New Prague
- Minnesota
- 56071
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ELMD | AMEX (NYSE MKT LLC) | Yes | Common Stock | US | USD | Aug 2010 |
Biography
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to patients with compromised pulmonary function; and SmartVest SQL System that provides advanced generator programmability and an enhanced pause feature with save, lock, and restore functionality. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers working in intensive care units; and Aerobika, an oscillating positive expiratory pressure device. The company offers its products primarily to home health care market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 00:55 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.